Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

CervoMed Inc

Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023 CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with Lewy bodies and other degenerative diseases of the brain CervoMed has a cash runway through Phase 2b clinical data which is expected during 2H 2024 BOSTON , Aug. 16, 2023 /PRNewswire/ -- CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced the closing of its previously announced merger with EIP Pharma Inc. The combined company will operate under the name CervoMed Inc., and its shares will commence trading on a 1-for-1.5 reverse split adjusted basis on August 17, 2023, on the Nasdaq Capital Market under the ticker symbol "CRVO". CervoMed's focus will be on advancing its lead drug candidate neflamapimod, an oral stress kinase inhibitor, which is currently being developed for the treatment of dementia with Lewy bodies (DLB) and other degenerative diseases of the brain.

CervoMed Announces Completion of Merger with EIP Pharma

Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

Extra Space Storage

Heska

Life Storage

NEW YORK , April 3, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Heska Corporation (NASDAQ: HSKA)'s  sale to Mars, Incorporated for $120.00 per share. If you are a Heska shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Diffusion Pharmaceuticals Inc. (the “Company”) (NasdaqCM: DFFN) with EIP Pharma Inc. pursuant to which Diffusion shareholders will end up owning 22.75% of the total number of outstanding shares of the combined company, subject to adjustment.

DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) and EIP Pharma Inc. is fair to Diffusion shareholders. Halper Sadeh encourages Diffusion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

DFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to Shareholders

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

CHARLOTTESVILLE, Va., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today sent a letter to its stockholders. The letter highlights the strength, experience and quality of the Company's board of directors as it continues to take steps to unlock stockholder value through a strategic review process. The letter also summarizes the value-destructive acquisition offer presented by LifeSci Capital on behalf of a purported client, the dismal track record of LifeSci Capital and its many affiliates in the biopharmaceutical space, and LifeSci-affiliated funds' recent nomination of an unqualified dissident slate of nominees for election as directors at the Company's 2022 Annual Meeting of Stockholders (the “Annual Meeting”).

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci's History of Stockholder Value Destruction and Self-Dealing

CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended September 30, 2022, and provided a business update.

Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process

Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that its Board of Directors (the “Board”) has authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value including transactional opportunities to better leverage the potential of trans sodium crocetinate (“TSC”) and the Company's other assets.

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC

•  Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022 •  Reported Positive Effects in TSC Altitude Trial •  Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities •  Expected Cash Runway into First Quarter of 2024

Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies to enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that after collaboration with the United States Food and Drug Administration (“FDA”) on the design of their Phase 2 clinical trial entitled “Open-Label, Dose-Escalation, Phase 2 Safety and Efficacy Study of TSC in Newly Diagnosed Glioblastoma (“GBM”) Patients when Administered with Standard of Care (“SOC”)”. The trial will be designated Study 200-208. The Company expects to initiate the trial by the end of 2022 and anticipates dosing the first patient in the trial in the first quarter of 2023.

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced positive effects from its second Oxygenation Trial, the Altitude Trial.

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., the Company's President and Chief Executive Officer, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement.

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

Lion Group Holding

Sunshine Biopharma

Sono Group NV

Tuscan Holdings Corp II

A circuit breaker is an automatic, temporary trading halt on specific securities when the underlying stock is experiencing times of high volatility. It is a measure to help restore and bring order to the markets.

5 Stocks Halted In Tuesday's Session

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) announced it will effect a 1-for-50 reverse stock split of its common stock. These are the details.

Diffusion Pharmaceuticals (DFFN) Stock: 1-For-50 Reverse Stock Split Announced

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) will effect a 1-for-50 reverse stock split of its common stock.  The reverse stock split is expected to become effective and commence trading on a post-split basis at the market's opening on April 19.

Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares are trading lower by 20.83% at $0.21 after the company announced a 1-for-50 reverse stock split. Diffusion Pharmaceuticals says the reverse stock split is expected to become effective at 5:59 p.m.

Why Diffusion Pharmaceuticals Shares Are Falling

Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022 Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022

Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T. • No Change to Meeting Location, Record Date, or Proposals to Be Voted Upon

Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders

CHARLOTTESVILLE, Va., March 21, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for 2021 and provided a business update.

News for Diffusion Pharmaceuticals Stock (DFFN)